Histogen Inc. Announces Board Changes
March 11, 2021 at 02:40 am IST
On March 10, 2021, Yizhuo Zhang resigned as a Director of Histogen Inc. effective immediately. Mr. Zhang's resignation from the Board of Directors was not a result of a disagreement on any matter relating to the Company's operations, policies or practices. Mr. Zhang also resigned as a member of the Nominating and Governance Committee of the Board. On March 10, 2021, the Board, following the recommendation of the Nominating and Corporate Governance Committee of the Board, elected Susan R. Windham-Bannister, Ph.D. to serve as a director of the Company, effective immediately. Dr. Windham-Bannister will serve as a Class II director and will stand for re-election to the Board at the Company's 2021 Annual Meeting of Stockholders. With Mr. Zhang's resignation from the Board, the size of the Board remains at eight members with the appointment of Dr. Windham-Bannister to the Board, five of which are independent, non-employee directors. Dr. Windham-Bannister, age 69, currently serves as President and CEO of Biomedical Growth Strategies., LLC a strategic advisory firm serving the healthcare industry which she founded with Dr. Harvey Lodish, co-founder of Genzyme.